I think the positive decision for Teva may bode well for both Teva's existing partners and potential partners. I questioned before if Teva's partnership with OGXI, for instance, might be on the chopping block given the new CEO but perhaps the litigation win makes it more likely that Teva will see existing partnerships through (if they otherwise deem them promising, of course). I also wonder if Teva will be more aggressive in inking new partnerships now. In particular, wondering if Teva has an eye on XNPT's XP23829 given their obvious interest in the MS space.
Market Data 
Markets 
AI
